Business Information
The group's principal activity is to develop, manufacture and sell human therapeutics for life-threatening diseases. The group uses technologies, which include the polyethylene glycol technology (peg) and single-chain antibodies technology (sca), for the development of such therapeutics. The polyethylene glycol technology is used to improve the delivery, safety and efficacy of proteins and small molecules with known therapeutic efficacy. The single-chain antibody technology is used to discover and produce antibody-like molecules that offer many of the therapeutic benefits of monoclonal antibodies. The group's products include abelcet, adagen, depocyt and oncaspar.
|
|
Name |
Title
|
Email
|
| Jeffrey Buchalter | Chmn., CEO | N/A | | Craig Tooman | CFO, Exec. VP - Finance | N/A | | Ivan Horak | Exec. VP - Research, Development, Chief Scientific Officer | N/A | | Paul Davit | Exec. VP - Human Resources | N/A | | Ralph Campo | Exec. VP - Technical Operations | N/A |
|
|
Year |
Sales |
Net Income |
| 2005 | 166,250 | (89,606) | | 2006 | 185,653 | 21,309 | | 2005 | 73,699 | (291,337)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
